Rheumatology in Perspective · by Olga Goodman, MD · A RheumaView publication
NSAIDs, Injections, and Conventional DMARDs
Understand what each treatment is meant to do, why the site of inflammation changes the plan, and which practical questions help a child or teenager live with that plan.
Which problem is this medicine treating?
A family may hear several medicine names at one appointment and leave with one question: why does our child need this particular combination? Start by asking the team to name the treatment target. A swollen knee, inflammation where a tendon attaches to bone, and inflammation in the sacroiliac joints are different problems, even when they belong to the same disease.
The plan also considers eye or bowel disease, previous treatment, daily function and the child’s preferences. A medicine can have a useful role for one part of the illness without treating every part. Ask for that role to be written beside its name.
NSAIDs can ease pain and inflammation
Nonsteroidal anti-inflammatory drugs, or NSAIDs, include medicines such as ibuprofen and naproxen. They can reduce pain and stiffness and help a child move more comfortably. Improvement in pain does not, on its own, show that all inflammation has settled or remove the need for follow-up.
These medicines still need an individual safety plan. Stomach problems, bleeding and kidney effects are among their possible harms. Tell the team about bowel disease, kidney problems, previous reactions and other medicines. Check an over-the-counter product with a pharmacist before adding it: different brand names can contain the same drug or another NSAID. Do not combine NSAIDs on your own.
Children do not all follow one medicine ladder
The ACR 2026 JIA summary recommends disease-modifying treatment from the outset for active enthesitis, with NSAIDs considered as an addition. For juvenile axial SpA, the separate 2026 summary conditionally supports an NSAID as initial treatment, while allowing earlier biologic or targeted treatment when the child is at risk of poor outcomes.
These are different clinical situations, not competing instructions for a family to choose between. Ask which situation the clinician is treating. A child does not have to pass through a universal sequence of increasingly “strong” medicines before the team can address the important problem.
A joint injection treats a particular joint
A corticosteroid injection can place anti-inflammatory medicine inside an affected joint. It may help when a small number of peripheral joints remain troublesome, or form one part of a wider treatment plan. Treating a knee locally does not automatically treat inflammation elsewhere.
Ask how the procedure will be made manageable. Depending on the child and procedure, the service may discuss local pain relief, sedation or anaesthesia. Explain needle fear and sensory needs beforehand. Obtain the service’s own preparation and aftercare instructions. Increasing pain, redness or swelling around the treated joint, or fever after the procedure, needs immediate medical advice rather than an assumption that it is an expected reaction.
An injection near a tendon attachment is a different decision
An enthesis is where a tendon or ligament attaches to bone. A sore heel does not automatically call for a local steroid injection. The pediatric section of the ACR 2026 axial SpA summary conditionally advises against injections around an inflamed enthesis. This is different from its recommendations about injections inside peripheral joints.
The precise structure matters. Ask what is causing the pain and what the proposed treatment would reach. Footwear, activity adjustments and rehabilitation may also belong in the plan, alongside treatment of inflammatory disease.
Conventional DMARDs address ongoing inflammatory disease
DMARD means disease-modifying antirheumatic drug. Conventional DMARDs include methotrexate and sulfasalazine. They are different from quick pain relief: the team prescribes them to control inflammatory disease over time. They may have a role in peripheral arthritis and selected treatment plans involving enthesitis.
Methotrexate is not a treatment for axial inflammation itself. A teenager with sacroiliitis may nevertheless receive it for a separate reason, such as peripheral joint disease. If two medicines are prescribed, ask what each contributes. “Why this drug?” is a reasonable question even when the medicine is familiar to another family.
Make the practical burden visible
Methotrexate can be given by mouth or by an injection under the skin. The choice involves tolerability, the clinical plan and the young person’s experience. For arthritis, methotrexate is taken once a week, not every day; follow the exact prescription and check any uncertainty with the pharmacist or team. Its use in childhood inflammatory disease is different from the much higher doses used in cancer care. Hearing the same medicine name in those settings does not mean that the treatments are equivalent.
Nausea, difficulty swallowing, anticipation of an injection or feeling unwell around treatment can disrupt school and family routines. Tell the team early, including when anxiety begins before the medicine is given. There may be ways to make treatment more tolerable. Do not quietly change the prescribed schedule to make the problem disappear.
Monitoring belongs to the treatment, too
Some medicines require blood counts and liver or kidney checks. The tests and timing depend on the drug and the individual child. A child who feels well may still need these checks. Before leaving, establish who orders tests, who reviews the results and how the family will hear about a result that changes the plan.
Keep an accurate medicine list, including non-prescription products and supplements. Bring a photograph of the label if names or formulations are confusing. A new prescription from another service should be checked against that list rather than relying on everyone to remember the arthritis treatment.
Give the young person a part in the conversation
A teenager may care most about nausea during lessons, privacy when taking medicine or missing a match for an appointment. Those concerns are clinically useful information. They help the team understand whether the plan is workable.
Responsibility can increase gradually: knowing a medicine’s name, explaining its purpose, remembering the next blood test, then learning whom to contact. A parent can remain a safety net. Transition to adult care is easier when the record explains why a treatment helped, failed or became difficult to tolerate.
Leave with a plan you can explain back
- Which joint, enthesis or other disease feature is each medicine intended to treat?
- What improvement should we look for, and when will the team review it?
- Which monitoring is needed, and who follows the results?
- Whom do we contact about side effects, illness or a prescription problem?
- What written advice applies to this exact product?
There is no dose chart or home treatment sequence in this chapter. The useful outcome is a shared explanation of the prescription, a realistic review date and a contact route that works between appointments.
Sources and further reading
- ACR 2026 JIA summary: enthesitis and peripheral treatment
- ACR/SAA/SPARTAN 2026 axSpA summary: pediatric treatment, pages 16–18
- ACR: current JIA guideline publication status
- ACR: NSAIDs — benefits, interactions and adverse effects
- Cambridge University Hospitals: children and young people having a joint injection
- Great Ormond Street Hospital: methotrexate for chronic inflammatory conditions
- ACR 2021 JIA guideline: medicine monitoring